ATC Group: N06AX23 Desvenlafaxine

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of N06AX23 in the ATC hierarchy

Level Code Title
1 N Nervous system
2 N06 Psychoanaleptics
3 N06A Antidepressants
4 N06AX Other antidepressants
5 N06AX23 Desvenlafaxine

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 50 mg

Related product monographs

Title Information Source Document Type  
DEPVEN XL Extended release tablet Health Products Regulatory Authority (ZA) MPI, Generic
PRISTIQ Extended-release tablet FDA, National Drug Code (US) MPI, US: SPL/PLR

Medicines in this ATC group

United States (US)

Australia (AU)

Canada (CA)

Hong Kong (HK)

Mexico (MX)

Singapore (SG)

South Africa (ZA)

Spain (ES)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.